Cargando…

Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice

BACKGROUND: The Bipolar Comprehensive Outcomes Study (BCOS) is a 2-year, prospective, non-interventional, observational study designed to explore the clinical and functional outcomes associated with ‘real-world’ treatment of participants with bipolar I or schizoaffective disorder. All participants r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Jayashri, Filia, Sacha, Berk, Lesley, Filia, Kate, Dodd, Seetal, de Castella, Anthony, Brnabic, Alan JM, Lowry, Amanda J, Kelin, Katarina, Montgomery, William, Fitzgerald, Paul B, Berk, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570370/
https://www.ncbi.nlm.nih.gov/pubmed/23244301
http://dx.doi.org/10.1186/1471-244X-12-228
_version_ 1782259058611322880
author Kulkarni, Jayashri
Filia, Sacha
Berk, Lesley
Filia, Kate
Dodd, Seetal
de Castella, Anthony
Brnabic, Alan JM
Lowry, Amanda J
Kelin, Katarina
Montgomery, William
Fitzgerald, Paul B
Berk, Michael
author_facet Kulkarni, Jayashri
Filia, Sacha
Berk, Lesley
Filia, Kate
Dodd, Seetal
de Castella, Anthony
Brnabic, Alan JM
Lowry, Amanda J
Kelin, Katarina
Montgomery, William
Fitzgerald, Paul B
Berk, Michael
author_sort Kulkarni, Jayashri
collection PubMed
description BACKGROUND: The Bipolar Comprehensive Outcomes Study (BCOS) is a 2-year, prospective, non-interventional, observational study designed to explore the clinical and functional outcomes associated with ‘real-world’ treatment of participants with bipolar I or schizoaffective disorder. All participants received treatment as usual. There was no study medication. METHODS: Participants prescribed either conventional mood stabilizers (CMS; n = 155) alone, or olanzapine with, or without, CMS (olanzapine ± CMS; n = 84) were assessed every 3 months using several measures, including the Young Mania Rating Scale, 21-item Hamilton Depression Rating Scale, Clinical Global Impressions Scale – Bipolar Version, and the EuroQol Instrument. This paper reports 24-month longitudinal clinical, pharmacological, functional, and socioeconomic data. RESULTS: On average, participants were 42 (range 18 to 79) years of age, 58%; were female, and 73%; had a diagnosis of bipolar I. Polypharmacy was the usual approach to pharmacological treatment; participants took a median of 5 different psychotropic medications over the course of the study, and spent a median proportion of time of 100%; of the study on mood stabilizers, 90%; on antipsychotics, 9%; on antidepressants, and 5%; on benzodiazepines/hypnotics. By 24 months, the majority of participants had achieved both symptomatic and syndromal remission of both mania and depression. Symptomatic relapse rates were similar for both the CMS alone (65%;) and the olanzapine ± CMS (61%;) cohorts. CONCLUSIONS: Participants with bipolar I or schizoaffective disorder in this study were receiving complex medication treatments that were often discordant with recommendations made in contemporary major treatment guidelines. The majority of study participants demonstrated some clinical and functional improvements, but not all achieved remission of symptoms or syndrome.
format Online
Article
Text
id pubmed-3570370
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35703702013-02-13 Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice Kulkarni, Jayashri Filia, Sacha Berk, Lesley Filia, Kate Dodd, Seetal de Castella, Anthony Brnabic, Alan JM Lowry, Amanda J Kelin, Katarina Montgomery, William Fitzgerald, Paul B Berk, Michael BMC Psychiatry Research Article BACKGROUND: The Bipolar Comprehensive Outcomes Study (BCOS) is a 2-year, prospective, non-interventional, observational study designed to explore the clinical and functional outcomes associated with ‘real-world’ treatment of participants with bipolar I or schizoaffective disorder. All participants received treatment as usual. There was no study medication. METHODS: Participants prescribed either conventional mood stabilizers (CMS; n = 155) alone, or olanzapine with, or without, CMS (olanzapine ± CMS; n = 84) were assessed every 3 months using several measures, including the Young Mania Rating Scale, 21-item Hamilton Depression Rating Scale, Clinical Global Impressions Scale – Bipolar Version, and the EuroQol Instrument. This paper reports 24-month longitudinal clinical, pharmacological, functional, and socioeconomic data. RESULTS: On average, participants were 42 (range 18 to 79) years of age, 58%; were female, and 73%; had a diagnosis of bipolar I. Polypharmacy was the usual approach to pharmacological treatment; participants took a median of 5 different psychotropic medications over the course of the study, and spent a median proportion of time of 100%; of the study on mood stabilizers, 90%; on antipsychotics, 9%; on antidepressants, and 5%; on benzodiazepines/hypnotics. By 24 months, the majority of participants had achieved both symptomatic and syndromal remission of both mania and depression. Symptomatic relapse rates were similar for both the CMS alone (65%;) and the olanzapine ± CMS (61%;) cohorts. CONCLUSIONS: Participants with bipolar I or schizoaffective disorder in this study were receiving complex medication treatments that were often discordant with recommendations made in contemporary major treatment guidelines. The majority of study participants demonstrated some clinical and functional improvements, but not all achieved remission of symptoms or syndrome. BioMed Central 2012-12-17 /pmc/articles/PMC3570370/ /pubmed/23244301 http://dx.doi.org/10.1186/1471-244X-12-228 Text en Copyright ©2012 Kulkarni et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kulkarni, Jayashri
Filia, Sacha
Berk, Lesley
Filia, Kate
Dodd, Seetal
de Castella, Anthony
Brnabic, Alan JM
Lowry, Amanda J
Kelin, Katarina
Montgomery, William
Fitzgerald, Paul B
Berk, Michael
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
title Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
title_full Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
title_fullStr Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
title_full_unstemmed Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
title_short Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
title_sort treatment and outcomes of an australian cohort of outpatients with bipolar i or schizoaffective disorder over twenty-four months: implications for clinical practice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570370/
https://www.ncbi.nlm.nih.gov/pubmed/23244301
http://dx.doi.org/10.1186/1471-244X-12-228
work_keys_str_mv AT kulkarnijayashri treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT filiasacha treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT berklesley treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT filiakate treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT doddseetal treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT decastellaanthony treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT brnabicalanjm treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT lowryamandaj treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT kelinkatarina treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT montgomerywilliam treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT fitzgeraldpaulb treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice
AT berkmichael treatmentandoutcomesofanaustraliancohortofoutpatientswithbipolariorschizoaffectivedisorderovertwentyfourmonthsimplicationsforclinicalpractice